Management of Residual Mass in Germ Cell Tumors After Chemotherapy

[1] Hendry WF(2002)Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses Cancer 94 1668-1676

[2] Norman AR(2009)Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection Eur Urol 55 217-224

[3] Dearnaley DP(2017)Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update BJU Int 120 104-108

[4] Fisher C(2007)Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma J Clin Oncol 25 1033-1037

[5] Nicholls J(2009)Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery J Urol 181 2526-2532

[6] Huddart RA(2010)Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 531-536

[7] Horwich A(2010)Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 28 537-542

[8] Heidenreich A(1998)Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience J Clin Oncol 16 702-706

[9] Pfister D(2018)ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up Ann Oncol 29 1658-1686

[10] Witthuhn R(2009)Management of the post chemotherapy subcentimeter residual mass: the case for observation World J Urol 27 485-488

[1] Hendry WF(2002)Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses Cancer 94 1668-1676

[2] Norman AR(2009)Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection Eur Urol 55 217-224

[3] Dearnaley DP(2017)Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update BJU Int 120 104-108

[4] Fisher C(2007)Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma J Clin Oncol 25 1033-1037

[5] Nicholls J(2009)Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery J Urol 181 2526-2532

[6] Huddart RA(2010)Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 531-536

[7] Horwich A(2010)Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 28 537-542

[8] Heidenreich A(1998)Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience J Clin Oncol 16 702-706

[9] Pfister D(2018)ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up Ann Oncol 29 1658-1686

[10] Witthuhn R(2009)Management of the post chemotherapy subcentimeter residual mass: the case for observation World J Urol 27 485-488